Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · Spain

Advanced Solid Tumors Trials in Spain, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5909 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:19 UTC
5909
Studies in scope
all four open statuses
3100
Recruiting now
open to new participants
1129
Lead sponsors
across recruiting studies
Top sites
Madrid 36 Barcelona 34 Valencia 9 Pamplona 9 Málaga 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Bayer3 AbbVie3 Merck Sharp & Dohme LLC3 Gilead Sciences2 Bristol-Myers Squibb2 Vividion Therapeutics, Inc.2 Novartis Pharmaceuticals1 AstraZeneca1 Marengo Therapeutics, Inc.1 EMD Serono Research & Development Institute, Inc.1 ModernaTX, Inc.1 MedImmune LLC1 Ottimo Pharma Limited1 Genentech, Inc.1 Regeneron Pharmaceuticals1 Zymeworks BC Inc.1 Janssen Research & Development, LLC1 Amgen1 Samsung Bioepis Co., Ltd.1 Abalos Therapeutics GmbH1 Atavistik Bio, Inc1 Eikon Therapeutics1 Hoffmann-La Roche1 Genmab1 Incyte Corporation1 Show all 27
Site location
Madrid36 Barcelona34 Valencia9 Pamplona9 Málaga6 Seville6 L'Hospitalet de Llobregat5 Logroño3 Badalona2 Pozuelo de Alarcón2 Santiago de Compostela2 Jaén2 Rioja1 Sant Cugat del Vallès1 Córdoba1 Majadahonda1 Palma1 Zaragoza1 Argentona1 A Gudiña1 Las Cabezas de San Juan1 Alcorcón1
All 22 locations
Target enrolment
to

Advanced Solid Tumors trials in Spain

36 of 5909 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Gilead Sciences
Phase 1
174
Barcelona, Madrid
2026-06-02
Recruiting
Genmab
Phase 1
121
Logroño, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid
2026-04-07
Recruiting
Samsung Bioepis Co., Ltd.
Phase 1
149
Barcelona, Madrid
2026-03-23
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Barcelona, Madrid
2026-02-13
Recruiting
Eikon Therapeutics
Phase 1/2
160
Palma, Barcelona, Logroño, Madrid, Zaragoza
2026-01-20
Recruiting
Ottimo Pharma Limited
Phase 1/2
170
Barcelona, Madrid, Rioja
2025-12-17
Recruiting
AstraZeneca
Phase 1
40
Barcelona, Madrid
2025-11-25
Recruiting
Abalos Therapeutics GmbH
Phase 1
27
Barcelona, Madrid
2025-10-14
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
Madrid
2025-07-29
Recruiting
Pyxis Oncology, Inc
Phase 1/2
220
Barcelona, Madrid, Valencia
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga
2025-03-25
Recruiting
Bristol-Myers Squibb
Phase 1/2
286
Barcelona, Pamplona, Madrid
2025-02-17
Recruiting
Bayer
Phase 2
111
L'Hospitalet de Llobregat, Barcelona, Madrid
2025-02-13
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Barcelona, Madrid
2024-12-13
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Barcelona, Córdoba, Madrid, Valencia
2024-10-30
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
Barcelona, Madrid
2024-02-26
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Barcelona, Madrid, Pamplona, Valencia
2024-01-25
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Barcelona, Madrid
2023-12-14
Recruiting
Vividion Therapeutics, Inc.
Phase 1
290
Barcelona, Madrid, Pamplona, Valencia
2023-07-28
Recruiting
Incyte Corporation
Phase 1
570
Barcelona, Madrid
2023-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 1
95
L'Hospitalet de Llobregat, Madrid, Barcelona, Seville
2023-07-06
Active, closed
Bristol-Myers Squibb
Phase 1/2
100
Málaga, Badalona, Pamplona, Madrid
2023-06-06
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
DrugSTAR0602
Marengo Therapeutics, Inc.
Phase 1/2
366
Barcelona, Madrid, Valencia
2023-01-04
Active, closed
AbbVie
Phase 1
288
Barcelona, Madrid, Seville, Valencia
2022-12-05
Active, closed
Bayer
Phase 1
284
Pamplona, Barcelona, Madrid
2022-11-04
Active, closed
Bayer
Phase 1
129
Pamplona, Barcelona, Madrid
2022-10-11
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Logroño, Barcelona, Madrid, Málaga
2022-09-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Madrid, Barcelona
2021-12-17
Active, closed
AbbVie
Phase 1
520
Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville
2021-10-13
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
548
Sant Cugat del Vallès, Pozuelo de Alarcón, Barcelona, Madrid, Valencia
2020-12-21
Active, closed
Hoffmann-La Roche
Phase 1/2
210
Argentona, Santiago de Compostela, A Gudiña, Las Cabezas de San Juan, Barcelona, Jaén, Madrid, Seville
2020-09-03
Active, closed
Genentech, Inc.
Phase 1
498
Barcelona, Madrid, Málaga, Seville, Valencia
2020-07-29
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Afatinib·Sotorasib
Amgen
Phase 1
610
Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid
2019-12-17
Active, closed
Novartis Pharmaceuticals
Phase 1
120
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2019-10-30
Active, closed
AbbVie
Phase 1
150
Barcelona, Madrid, Málaga
2019-05-21
Active, closed
MedImmune LLC
Phase 1/2
383
Barcelona, Madrid, Málaga, Pamplona, Seville
2016-02-22
Rows per page Showing 1–36 of 36
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-spain/condition/advanced-solid-tumors

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,909 studies in total at the last sync on 13 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 36 of those studies listing the condition Advanced Solid Tumors.

How many Advanced Solid Tumors trials are recruiting in Spain?

20 of the 36 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumors), 36 studies
PhaseStudiesRecruitingShare
Phase 1231163.9%
Phase 1/212833.3%
Phase 2112.8%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumors)
Lead sponsorStudiesRecruiting
AbbVie30
Bayer31
Merck Sharp & Dohme LLC32
Bristol-Myers Squibb21
Gilead Sciences22
Vividion Therapeutics, Inc.22
Abalos Therapeutics GmbH11
Amgen10
AstraZeneca11
Atavistik Bio, Inc10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.